Ra­dioan­ti­body start­up led by prostate can­cer ex­perts rais­es $90M

Neil Ban­der’s lab de­vel­oped the first an­ti­bod­ies that tar­get PS­MA — a mark­er on prostate can­cer cells that would much lat­er be­come the tar­get for No­var­tis …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER